An interventional study of Mepivacaine and Articaine in Symptomatic Irreversible Pulpitis, sponsored by Cairo University. Completed. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2021-08-02.
Sponsored by Cairo University · Not applicable, Interventional, and Prevention
The aim of this randomized, double-blinded, clinical trial was to assess the effect of 3.6 mL 2% mepivacaine hydrochloride with 1:100,000 epinephrine compared to 3.4 mL 4% articaine hydrochloride with 1:100,000 epinephrine on the success of the inferior alveolar nerve block for patients with symptomatic irreversible pulpitis in mandibular molars.
The aim of this randomized, double-blinded, clinical trial was to assess the effect of 3.6 mL 2% mepivacaine hydrochloride with 1:100,000 epinephrine compared to 3.4 mL 4% articaine hydrochloride with 1:100,000 epinephrine on the success of the inferior alveolar nerve block for patients with symptomatic irreversible pulpitis in mandibular molars. Patients were clinically and radiographically examined and their eligibility assessed and preoperative pain was measured using the numerical rating scale (NRS). Patients were randomly assigned to one of 2 groups: experimental group (2% mepivacaine) and the control group (4% articaine). After 15 minutes of the inferior alveolar nerve block (IANB), patients reporting lip numbness had their molars accessed. No-to-mild pain response was considered success during root canal preparation.
302 studies on the registry are indexed under Pulpitis; 67 are open to participants now.
This study's enrollment of 330 is above the median of 62 across 275 interventional studies indexed under Pulpitis.
Browse Pulpitis studies →Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.
Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.
Drug: Mepivacaine
IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.
Drug: Articaine
IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.
IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.
Anaesthetic success
Success of mandibular inferior alveolar nerve block anesthesia during access cavity preparation and instrumentation measured using the 11-point numerical rating scale (NRS) so that no-or-mild pain is considered as anesthetic success and moderate-to-severe pain is considered anesthetic failure.
Time frame: Intraoperative
Need for Supplemental anaesthesia
The need for supplemental anaesthesia to complete treatment (Yes/No).
Time frame: Intraoperative
No study locations are listed for this record.
Plan to share: Undecided
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cairo University